1-2 of 2
Ruth Moser
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer

Michael Mattie, Arthur Raitano, Kendall Morrison, Karen Morrison, Zili An, Linnette Capo, Alla Verlinsky, Monica Leavitt, Jimmy Ou, Rossana Nadell, Hector Aviña, Claudia Guevara, Faisal Malik, Ruth Moser, Steven Duniho, Jeffrey Coleman, Ying Li, Daniel S. Pereira, Fernando Doñate, Ingrid B.J. Joseph, Pia Challita-Eid, Dennis Benjamin, David R. Stover
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2679–2687.
https://doi.org/10.1158/1535-7163.MCT-16-0225
Published: 01 November 2016
View articletitled, The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Open the PDF for The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

The use of pharmacokinetic and pharmacodynamic data to optimize the dose and schedule of an EphA2 antibody drug conjugate in-vivo

Krista Kinneer, Maria Camara, Shenlan Mao, John Gooya, Ruth Moser, Damon Meyer, Peter Senter, Peter Kiener, Steve Coats, Bahija Jallal, David Tice, Dowdy Jackson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B61.
Published: 01 November 2007
View articletitled, The use of pharmacokinetic and pharmacodynamic data to optimize the dose and schedule of an EphA2 antibody drug conjugate in-vivo